Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN... - MPN Voice

MPN Voice

10,437 members14,387 posts

Dr Kiladjian at ASH 2016 Reviews Outcomes of MPN Patients after Interferon therapy discontinuation

PVReporter profile image
4 Replies

Early Treatment with Interferon provides better Patient Outcomes - Second in ASH 2016 Series, PV Reporter - pvreporter.com/dr-kiladjian...

Written by
PVReporter profile image
PVReporter
To view profiles and participate in discussions please or .
Read more about...
4 Replies
crapaud profile image
crapaud

Very interesting - I was part of the 15% who were taken off Pegasys not for toxicity or remission reasons; JJK advised me to stop Pegasys and go for a SCT.

Such a humble and approachable man.

Thanks for the reporting.

Crapaud

PVReporter profile image
PVReporter in reply to crapaud

I hope your SCT has gone well. Glad you enjoyed the interview. I was excited to get the opportunity, it was a pleasure to discuss his latest research on interferon

Best,

David - PV Reporter

crapaud profile image
crapaud in reply to PVReporter

Thanks David,

The SCT in itself went pretty well, a few lingering cGvHD setbacks still need to be fully sorted - but hey!! I'm here, spent Christmas with my loved ones and have lots of outstanding personal projects that I can look forward to.

Best regards Crapaud

PVReporter profile image
PVReporter

That's good news Crapaud, I hope you get the cGvHD smoothed out. Always nice to spend time with the family and have future projects to keep you busy!

Best,

David

You may also like...

ASH paper re younger MPN patients, dx age <= 40

younger MPN patients so thought I would highlight this one that is being presented at the ASH...

A Conversation with an MPN Specialist: ASH Updates - Dr. Andrew Kuykendall

presentations from the recent meeting of ASH from our friends at MPN Advocacy & Education...

10 facts MPN patients need to know about FDA approval of Ropegylated interferon alpha2b (Besremi).

Cancer Center, and MPN expert and investigator, discusses the top 10 facts that patients with...

Dr Verstovsek on Besremi and Outcomes

targetedonc.com/view/first-fda-approved-interferon-improves-outcomes-in-polycythemia-vera

Interferons as the First Choice of Cytoreduction in ET and PV

used in the treatment of cancers, including hematologic malignancies. Use of standard interferon...